Cite

    Varma, P. et al. (2019). Immunomodulator use does not prevent first loss of response to anti‐tumour necrosis factor alpha therapy in inflammatory bowel disease: long‐term outcomes in a real‐world cohort. Internal medicine journal. 49 (6), pp. 753-760. [Online].